drugset / Trial / NCT07221032
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT836 CAR T cells | Cell therapy | 1e+08 cells | Intravenous |
| Subject | FT836 CAR T cells | Cell therapy | 3e+08 cells | Intravenous |
| Subject | FT836 CAR T cells | Cell therapy | 9e+08 cells | Intravenous |
| Background | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |